Advertisement

Picture biomindz Brand LSE Mainz Place to Biotech 650x100px
Organisation › Details

Sangamo Therapeutics Inc. (Nasdaq: SGMO)

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic™ development program is currently in Phase 2 clinical trials for evaluation of safety in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, ischemic heart disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF™) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN™) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. A portion of Sangamo's research in plant agriculture is supported by an Advanced Technology Program (ATP) grant awarded by the National Institute of Standards and Technology. Sangamo has also established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. *

 

Period Start 2018-07-23 renamed before
  Group Sangamo (Group)
  Predecessor Sangamo BioSciences Inc. (Nasdaq: SGMO)
Product Industry BIOTECH
Persons Person Macrae, Sandy (Sangamo 201807 CEO)
  Person 2 Lee, Sung (MorphoSys 202102–202303 CFO before Sangamo + Gilead Sciences LEFT 3/23)
     
  Street 501 Canal Boulevard
  City 94804 Richmond, CA
  Tel +1-510-970-6000
    Address record changed: 2024-08-08
     
Basic data Employees D: 101 to 500 (2023-12-31)
  Currency USD
  Annual sales 176,232,000 (revenues, annual, consolidated (2023) 2023-12-31)
  Profit -257,831,000 (2023-12-31)
  Cash 80,992,000 (2023-12-31)
     
    * Document for »About Section«: 
     
   
Record changed: 2024-08-14

Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

More documents for Sangamo (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture biomindz Mainz Biomed LSE Colorectal Cancer Screening 650x300px




» top